Icotinib
- Generic Name
- Icotinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H21N3O4
- CAS Number
- 610798-31-7
- Unique Ingredient Identifier
- 9G6U5L461Q
- Background
Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
...
- Indication
Icotinib hydrochloride is a novel epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor, exhibits encouraging efficacy and tolerability in patients with advanced non-small-cell lung cancer (NSCLC) who failed previous chemotherapy.
- Associated Conditions
- -
- Associated Therapies
- -
Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
- First Posted Date
- 2016-10-14
- Last Posted Date
- 2021-09-09
- Lead Sponsor
- Li Peng
- Target Recruit Count
- 10
- Registration Number
- NCT02934256
- Locations
- 🇨🇳
Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, China
First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation
- Conditions
- Interventions
- First Posted Date
- 2016-08-30
- Last Posted Date
- 2016-08-30
- Lead Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- Target Recruit Count
- 330
- Registration Number
- NCT02883543
The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation
- First Posted Date
- 2016-06-30
- Last Posted Date
- 2016-06-30
- Lead Sponsor
- Beijing Haidian Hospital
- Target Recruit Count
- 67
- Registration Number
- NCT02820116
- Locations
- 🇨🇳
Beijing Haidian Hospital, Beijing, Beijing, China
Conmana Combined With Thalidomide to Treat NSCLC
- First Posted Date
- 2016-05-20
- Last Posted Date
- 2016-05-20
- Lead Sponsor
- Henan Provincial People's Hospital
- Target Recruit Count
- 67
- Registration Number
- NCT02778893
- Locations
- 🇨🇳
XZhang, Zhengzhou, Henan, China
Cryotherapy Combine Icotinib for Advanced NSCLC Treatment
- First Posted Date
- 2016-04-20
- Last Posted Date
- 2020-05-27
- Lead Sponsor
- Fuda Cancer Hospital, Guangzhou
- Target Recruit Count
- 60
- Registration Number
- NCT02744664
Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation
- First Posted Date
- 2016-04-14
- Last Posted Date
- 2020-07-01
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT02737774
- Locations
- 🇨🇳
Henan cancer hospital, Zhengzhou, Henan, China
High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2016-04-01
- Last Posted Date
- 2019-02-19
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT02726568
- Locations
- 🇨🇳
West China Hospital, Chengdu, Sichuan, China
Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2015-07-01
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 128
- Registration Number
- NCT02486354
- Locations
- 🇨🇳
307 Hospital of PLA, Beijing, Beijing, China
🇨🇳Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
🇨🇳Third Affiliated Hospital, Third Military Medical University, Chongqing, Chongqing, China
Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation
- First Posted Date
- 2015-05-19
- Last Posted Date
- 2021-07-20
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 320
- Registration Number
- NCT02448797
- Locations
- 🇨🇳
307 Hospital of PLA, Beijing, Beijing, China
🇨🇳Fujian Provincal Cancer Hospital, Fuzhou, Fujian, China
🇨🇳The First Affiliated Hospital Of Guangzhou Medical Collage, Guangzhou, Guangdong, China
Chemotherapy of NSCLC With or Without Icotinib
- First Posted Date
- 2015-04-30
- Last Posted Date
- 2015-04-30
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 50
- Registration Number
- NCT02430974
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.